2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Indirect effect of alpha-1-antitrypsin on endotoxin-induced IL-1β secretion from human PBMCs

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Human alpha-1-antitrypsin (AAT) encoded by the SERPINA1 gene, is an acute phase glycoprotein that regulates inflammatory responses via both protease inhibitory and non-inhibitory activities. We previously reported that AAT controls ATP-induced IL-1β release from human mononuclear cells by stimulating the release of small bioactive molecules. In the current study, we aimed to elucidate the identity of these putative effectors released from human PBMCs in response to AAT, which may inhibit the LPS-induced release of IL-1β. We pre-incubated human PBMCs alone or with different preparations of AAT (4 mg/ml) for 30 min at 37°C, 5% CO 2, and collected cell supernatants filtered through centrifugal filters (cutoff 3 kDa) to eliminate AAT and other high molecular weight substances. Supernatants passed through the filters were used to culture PBMCs isolated from the autologous or a heterologous donors with or without adding LPS (1 μg/ml) for 6 h. Unexpectedly, supernatants from PBMCs pre-incubated with AAT (Zemaira ®), but not with other AAT preparations tested or with oxidized AAT (Zemaira ®), lowered the LPS-induced release of IL-1β by about 25%–60% without affecting IL1B mRNA. The reversed-phase liquid chromatography coupled with mass spectrometry did not confirm the hypothesis that small pro-resolving lipid mediators released from PBMCs after exposure to AAT (Zemaira ®) are responsible for lowering the LPS-induced IL-1β release. Distinctively from other AAT preparations, AAT (Zemaira ®) and supernatants from PBMCs pre-treated with this protein contained high levels of total thiols. In line, mass spectrometry analysis revealed that AAT (Zemaira ®) protein contains freer Cys232 than AAT (Prolastin ®). Our data show that a free Cys232 in AAT is required for controlling LPS-induced IL-1β release from human PBMCs. Further studies characterizing AAT preparations used to treat patients with inherited AAT deficiency remains of clinical importance.

          Related collections

          Most cited references83

          • Record: found
          • Abstract: found
          • Article: not found

          The MaxQuant computational platform for mass spectrometry-based shotgun proteomics.

          MaxQuant is one of the most frequently used platforms for mass-spectrometry (MS)-based proteomics data analysis. Since its first release in 2008, it has grown substantially in functionality and can be used in conjunction with more MS platforms. Here we present an updated protocol covering the most important basic computational workflows, including those designed for quantitative label-free proteomics, MS1-level labeling and isobaric labeling techniques. This protocol presents a complete description of the parameters used in MaxQuant, as well as of the configuration options of its integrated search engine, Andromeda. This protocol update describes an adaptation of an existing protocol that substantially modifies the technique. Important concepts of shotgun proteomics and their implementation in MaxQuant are briefly reviewed, including different quantification strategies and the control of false-discovery rates (FDRs), as well as the analysis of post-translational modifications (PTMs). The MaxQuant output tables, which contain information about quantification of proteins and PTMs, are explained in detail. Furthermore, we provide a short version of the workflow that is applicable to data sets with simple and standard experimental designs. The MaxQuant algorithms are efficiently parallelized on multiple processors and scale well from desktop computers to servers with many cores. The software is written in C# and is freely available at http://www.maxquant.org.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Reactive oxygen species (ROS) as pleiotropic physiological signalling agents

            'Reactive oxygen species' (ROS) is an umbrella term for an array of derivatives of molecular oxygen that occur as a normal attribute of aerobic life. Elevated formation of the different ROS leads to molecular damage, denoted as 'oxidative distress'. Here we focus on ROS at physiological levels and their central role in redox signalling via different post-translational modifications, denoted as 'oxidative eustress'. Two species, hydrogen peroxide (H2O2) and the superoxide anion radical (O2·-), are key redox signalling agents generated under the control of growth factors and cytokines by more than 40 enzymes, prominently including NADPH oxidases and the mitochondrial electron transport chain. At the low physiological levels in the nanomolar range, H2O2 is the major agent signalling through specific protein targets, which engage in metabolic regulation and stress responses to support cellular adaptation to a changing environment and stress. In addition, several other reactive species are involved in redox signalling, for instance nitric oxide, hydrogen sulfide and oxidized lipids. Recent methodological advances permit the assessment of molecular interactions of specific ROS molecules with specific targets in redox signalling pathways. Accordingly, major advances have occurred in understanding the role of these oxidants in physiology and disease, including the nervous, cardiovascular and immune systems, skeletal muscle and metabolic regulation as well as ageing and cancer. In the past, unspecific elimination of ROS by use of low molecular mass antioxidant compounds was not successful in counteracting disease initiation and progression in clinical trials. However, controlling specific ROS-mediated signalling pathways by selective targeting offers a perspective for a future of more refined redox medicine. This includes enzymatic defence systems such as those controlled by the stress-response transcription factors NRF2 and nuclear factor-κB, the role of trace elements such as selenium, the use of redox drugs and the modulation of environmental factors collectively known as the exposome (for example, nutrition, lifestyle and irradiation).
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Acute-Phase Proteins and Other Systemic Responses to Inflammation

                Bookmark

                Author and article information

                Contributors
                Journal
                Front Pharmacol
                Front Pharmacol
                Front. Pharmacol.
                Frontiers in Pharmacology
                Frontiers Media S.A.
                1663-9812
                30 September 2022
                2022
                : 13
                : 995869
                Affiliations
                [1] 1 Department of Respiratory Medicine , Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH) , Member of the German Center for Lung Research (DZL) , Hannover, Germany
                [2] 2 Department of Experimental Medicine , Lund University , Lund, Sweden
                [3] 3 Chair of Food Chemistry , Faculty of Mathematics and Natural Sciences , University of Wuppertal , Wuppertal, Germany
                [4] 4 Institute of Clinical Biochemistry , Hannover Medical School , Hannover, Germany
                [5] 5 Institute for Transfusion Medicine and Transplant Engineering , Hannover Medical School , Hannover, Germany
                [6] 6 Laboratory of Experimental Surgery , Department of General and Thoracic Surgery , Justus-Liebig-University Giessen , German Center for Lung Research , Giessen, Germany
                Author notes

                Edited by: Gerard Bannenberg, Global Organization for EPA and DHA Omega-3s (GOED), United States

                Reviewed by: Ronen Schuster, CytoReason, Israel

                Ritesh Sevalkar, University of Alabama at Birmingham, United States

                *Correspondence: Sabina Janciauskiene, janciauskiene.sabina@ 123456mh-hannover.de
                [ † ]

                These authors have contributed equally to this work

                This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology

                Article
                995869
                10.3389/fphar.2022.995869
                9564231
                36249781
                b2cfe4da-9829-4237-98c2-41cf56ebf7b3
                Copyright © 2022 Janciauskiene, Tumpara, Schebb, Buettner, Mainka, Sivaraman, Immenschuh, Grau, Welte and Olejnicka.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 16 July 2022
                : 13 September 2022
                Categories
                Pharmacology
                Original Research

                Pharmacology & Pharmaceutical medicine
                alpha-1-antitrypsin,pbmcs,lps,interleukin-1β,cytokines,supernatants,mass-spectrometry,total thiols

                Comments

                Comment on this article